Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report

Anti-tumour necrosis factor-alpha has dramatically changed the natural history of Crohn's disease in the last decades. Adalimumab is effective in inducing and maintaining clinical remission as well as in inducing deep mucosal healing, which is a prognostic factor for further progression of the disease. Long-term treatment with adalimumab is considered safe and should be continued for at least 3 years in patients with aggressive long-standing Crohn's disease.

We report the case of a 61-year-old woman with aggressive and complicated steroid-dependant Crohn's disease in whom clinical and endoscopic long-term deep remission was achieved for up to 3 years, without any need for steroids, hospitalization or surgery.